December 19, 2016
The filler market in the US expands with FDA approval of Galderma's Restylane Refyne and Restalyne Define for the treatment of nasolabial folds in patients over the age of 21. The gels are manufactured with XpresHAn Technology, which allows a range of flexibility and support for varied patient needs, the company says. Dermatology industry veteran William D. Humphries has been appointed Executive Vice President, Dermatology, at Valeant Pharmaceuticals effective January 2. And as 2016 comes to a close, we take a look at some of the notable approvals of the year.